Quantitative PSMA PET Biomarkers for Predicting Response to 177 Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis
Journal of Nuclear Medicine · 2026-06 · 67 (6) · 929-935
DOI: 10.2967/jnumed.125.270872 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 26.02.2026. Verfasst von Iman Kiani und 6 weiteren Autor:innen. Beteiligte Einrichtung: Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Antigens, Surface, Biomarkers, Tumor, Dipeptides, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
177Lu-labeled prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (177Lu-PSMA-617) has emerged as a promising targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). However, response rates to therapy vary among patients. Quantitative PSMA PET biomarkers have been increasingly explored for their prognostic potential in guiding patient selection. This systematic review and meta-analysis aims to evaluate the prognostic value of PSMA PET biomarkers for response to 177Lu-PSMA therapy in patients with mCRPC.
Methods
A systematic search was conducted across PubMed, Scopus, Web of Science, and Embase databases to identify studies evaluating quantitative PSMA PET parameters as predictors of response to 177Lu-PSMA therapy. Hazard ratios (HRs) and 95% CIs for quantitative PSMA PET parameters were extracted and synthesized using random-effects meta-analysis. Heterogeneity was assessed using I 2 statistics, and publication bias was evaluated via funnel plots and the Egger test.
Results
A total of 23 studies met the inclusion criteria. Among PSMA PET parameters, SUVmean, tumor volume (TV), or total lesion (TL) PSMA emerged as significant predictors of overall survival (OS), progression free survival, and prostate-specific antigen response. The pooled HR for SUVmean in predicting OS was 0.93 (95% CI, 0.90-0.96; I 2 = 92.8%), whereas TV showed a HR of 1.37 (95% CI, 1.27-1.47; I 2 = 4.7%), and the TL had a HR of 1.04 (95% CI, 1.03-1.05; I 2 = 16.1%). Additionally, SUVmax and SUVpeak demonstrated limited predictive value.
Conclusion
Our findings indicate that SUVmean, TV, and TL derived from PSMA PET imaging could serve as valuable biomarkers for prognosticating response to 177Lu-PSMA therapy in patients with mCRPC. Future studies should aim to integrate PET biomarkers with clinical and biochemical parameters to improve treatment decision-making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; and.
- Department of Nuclear Medicine and Theranostics, David Geffen School of Medicine, UCLA, Los Angeles, California asalavati@mednet.ucla.edu.
Zitieren
APA
Kiani, I., Siri, M. A., Babaei, M., Aliasghari, M. M., Mohammadzadeh, S., Mohammadi, S., & Salavati, A. (2026). Quantitative PSMA PET Biomarkers for Predicting Response to 177 Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis. Journal of Nuclear Medicine, 67(6), 929-935. https://doi.org/10.2967/jnumed.125.270872
Vancouver
Kiani I, Siri MA, Babaei M, Aliasghari MM, Mohammadzadeh S, Mohammadi S, et al. Quantitative PSMA PET Biomarkers for Predicting Response to 177 Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis. Journal of Nuclear Medicine. 2026;67(6):929-935. doi:10.2967/jnumed.125.270872
BibTeX
@article{Kiani2026,
author = {Kiani, Iman and Siri, Mohammad Amin and Babaei, Mahan and Aliasghari, Mohammad Mahdi and Mohammadzadeh, Saeed and Mohammadi, Sara and Salavati, Ali},
title = {Quantitative PSMA PET Biomarkers for Predicting Response to 177 Lu-PSMA Therapy in Prostate Cancer: A Systematic Review and Meta-analysis},
journal = {Journal of Nuclear Medicine},
year = {2026},
volume = {67},
number = {6},
pages = {929--935},
doi = {10.2967/jnumed.125.270872}
}
EUVIMED